Skip to Main Content

Now that the top Gilead Sciences (GILD) executives are leaving, will a full-blown exodus occur at the biotech?

The thought arises after the company announced on Wednesday that Dr. Andrew Cheng, a 19-year Gilead veteran who was named chief medical office just five months ago, is suddenly departing. His resignation follows by just three weeks the unexpected news that chief executive John Milligan will leave at the end of the year, after just two years in that role, and that chairman John Martin will follow suit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.